{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+NRTIs", "query": { "intervention": "2 NRTIs" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+NRTIs&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T03:59:51.733Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002447", "title": "A Study to Compare Two Anti-HIV Drug Combinations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Long Beach, California • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002447" }, { "nct_id": "NCT02140255", "title": "Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Nevirapine (NVP)", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Raltegravir (RAL)", "type": "DRUG" }, { "name": "VRC01", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "48 Hours", "sex": "ALL", "summary": "Up to 48 Hours" }, "enrollment_count": 1120, "start_date": "2015-01-23", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140255" }, { "nct_id": "NCT00039741", "title": "Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)", "type": "DRUG" }, { "name": "NNRTIs (EFV, NVP)", "type": "DRUG" }, { "name": "PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Days", "maximum_age": "18 Years", "sex": "ALL", "summary": "30 Days to 18 Years" }, "enrollment_count": 266, "start_date": "2002-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 29, "location_summary": "Alhambra, California • Long Beach, California • Los Angeles, California + 22 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039741" }, { "nct_id": "NCT00896051", "title": "TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "Atazanavir (ATV) 300 mg", "type": "DRUG" }, { "name": "Atazanavir (ATV) 400 mg", "type": "DRUG" }, { "name": "Ritonavir (rtv) 100 mg", "type": "DRUG" }, { "name": "Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Etravirine (ETR) 200 mg", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate (TDF) 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-08", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00896051" }, { "nct_id": "NCT00799864", "title": "A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "Rilpivirine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Abacavir", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 54, "start_date": "2011-01", "completion_date": "2022-08", "has_results": true, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 2, "location_summary": "Syracuse, New York • Memphis, Tennessee", "locations": [ { "city": "Syracuse", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799864" }, { "nct_id": "NCT00915655", "title": "A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "darunavir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "zidovudine", "type": "DRUG" }, { "name": "lamivudine", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Years to 18 Years" }, "enrollment_count": 12, "start_date": "2009-07", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-09-03", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00915655" }, { "nct_id": "NCT02422797", "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG 50 mg", "type": "DRUG" }, { "name": "RPV 25 mg", "type": "DRUG" }, { "name": "CAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2015-04-21", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 13, "location_summary": "Bakersfield, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422797" }, { "nct_id": "NCT01252940", "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/RPV/TDF", "type": "DRUG" }, { "name": "PI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2010-11", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01252940" }, { "nct_id": "NCT06630299", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "Antiretroviral Combinations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-08", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630299" }, { "nct_id": "NCT04272242", "title": "Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "LTBI" ], "interventions": [ { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Antiretroviral Therapy (ART)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2021-02-27", "completion_date": "2021-12-27", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-04T03:59:51.733Z", "location_count": 2, "location_summary": "San Francisco, California • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04272242" } ] }